Member Info for gadgie

Attendees ...David Wilson ...Petros Sarantos ...Rachel Mellick ..
https://www.medica-tradefair.com/vis/v1/en/exhibitors/medcom2022.2727408?oid=80396&lang=2&_query=avacta

The Affimer® platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

https://www.rapivd.com/news-resources

Avacta listed as Exhibitor ....Diagnostic Rapid Tests

https://www.compamed-tradefair.com/vis/v1/en/exhibitors/medcom2022.2727408

Avacta have been working on the following list for POC testing ... For sure Diagnostics Div will have a lot to reveal soon

? Respiratory diseases (e.g. COVID19, Flu A/B) ? Sexually transmitted diseases
? Sepsis/Bloodstream infections
? Antimicrobial resistance
? Congenital infections
? Cardiac disease (e.g. heart failure, AMI, stroke) ? Cancer markers
? Diabetes (e.g. HbA1c)
? Neurodegeneration (e.g. Alzheimer’s risk)
? Therapeutic drug monitoring
? Cancer markers ? Thyroid function ? Liver function
? Kidney function ? Heart function
? Hormones (e.g. Cortisol) ? Vitamins
? Iron
? Cholesterol
https://avacta.com/wp-content/uploads/2022/04/Avacta-Group-plc-Prelim-Results-2021-FINAL.pdf

Thankyou Excellent ....
Para Legal Ad
https://ckgroup.co.uk/job/Paralegal-legal-Assistant/171709686585346/
The Role of Paralegal.

You will play a critical role in formalizing and building Avacta’s legal capabilities for Therapeutics R& and will be responsible for engaging leaders to develop the overall legal vision and strategy and drive its execution. You will possess a proven track record of drafting and reviewing commercial, research, consultancy agreements and confidentiality disclosure agreements (CDAs).

Role & Responsibilities:

Engage senior leaders and other key stakeholders to ensure legal documents are managed accordingly and processes are optimised to support a fast-paced oncology-focused business
Support colleagues with their requests for legal documents
Draft legal document and proofread documents
Organise files of legal documents within the contracts database
Perform administration, including filing and logging of legal documents and letters
Coordinate efforts with key functions to support from a legal perspective: new strategic business opportunities, collaborations, acquisitions, partnerships, alliances, licensing deals, and/or joint ventures
Act as the point person forall legal matters
To be considered for the position, you should have the following skills:

Educated to degree level or above with a relevant legal qualification e.g. Graduate Diploma in Law as well as experience in the law sector and also within biopharma or commercialisation arm of an academic institute.
Excellent written and verbal communication skills
Competence in working with legal teams (and utilising input from other stakeholders) to review and edit contracts
The benefits: Avacta offer an exciting range of benefits which includes:

Private medical cover
Annual performance related bonus of up to 10% of salary
Life assurance
Company pension scheme
25 Days annual leave + Bank Holidays
Share Incentive Plans
Apply: It is essential that applicants hold entitlement to work in the UK. Please quote job reference 53261 in all correspondence.

A photo of Mary Bolt Senior Recruitment Consultant at CK Group

This multi-disciplinary project will build on technology developed by the Marsden group to develop molecular dyes incorporating ‘small bicyclic amine’ (SBA) modifiers that will improve their brightness/stability. The SBA molecules will be connected to cancer targeting agents (Affimers) developed by the Jayne and Khaled groups and industry partner (Avacta Life Sciences Ltd), creating a library of novel molecular tools for fluorescence-guided surgery and photodynamic therapy.

Objectives:

1) synthesise and characterise the photophysical properties of novel SBA-modified dyes absorbing in the tissue-penetrant near-infra-red range;

2) quantify in vitro performance of SBA-modified dyes as agents for photodynamic therapy;

3) optimise bioconjugation of SBA-modified dyes to cancer targeting agent (anti-CEA Affimers);

4) select the best performing SBA-modified dyes (targeted fluorescence; photodynamic efficacy) in colorectal cancer cell cultures.

https://www.findaphd.com/phds/project/mrc-dimen-doctoral-training-partnership-illuminating-cancer-therapy-novel-fluorescent-theranostics-for-precision-surgery/?p138401

We have the Updated LFT ready to go IMHO :
2022-08-24
https://covid-19-diagnostics.jrc.ec.europa.eu/devices/detail/2905

Results last year 30th Sept ( 6 Month's ) IMHO it's when we get some detailed info ......... Not Long all will be revealed ......

over the past week they have accumulated easy shares weak sellers ....seen it so many times over the year's
Easy Money

70 billion market dox alone :)
https://www.**********.co.uk/articles/paul-hill-sector-analysis-is-important-smart-meter-stocks-could-be-winners-e795127

need detective GMCC ....great spot

Generic Name: N-[(2R)-1-[(2S)-2-[(3-hydroxy-2-methyl-6-{[(3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl)carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]pyridine-4-carboxamide
Date Designated: 09/01/2022
Orphan Designation: Treatment of soft tissue sarcoma
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Sponsor: Avacta Life Sciences Ltd.
Scale Space, White City, Imperial College Campus
58 Wood Lane
London W12 7RZ
United Kingdom

The sponsor address listed is the last reported by the sponso

Hi 99.5% specificity upgraded .... also failure rate on affidX updated 1 fail in 102 tests ,,,, site down at mo ( type from memory )

Meduflow also updated

https://covid-19-diagnostics.jrc.ec.europa.eu/devices/detail/2905

https://covid-19-diagnostics.jrc.ec.europa.eu/devices/detail/2426

55.2 % Major Shareholders

https://m.marketscreener.com/quote/stock/AVACTA-GROUP-PLC-4004322/company/
plus :
https://fintel.io/so/gb/avct

Does anyone have any more up to date lists please

Apologies if already posted :
https://www.trinitydelta.org/wp-content/uploads/2022/06/AVCT-Lighthouse-220630.pdf
Once AVA6000 has established proof of concept, we expect increased industry interest in the pre|CISION platform. Avacta has identified other chemotherapies whose clinical utility would similarly benefit from improved efficacy and reduced toxicities. The most advanced is AVA3996, a prodrug of an analogue of Takeda’s Velcade (bortezomib), which is commonly used for multiple myeloma. AVA3996 offers the prospect of reducing the dose limiting toxicities, principally peripheral neuropathy and thrombocytopenia, that constrain Velcade use to multiple myeloma and mantle cell lymphoma.

Both could erupt anytime :)

Don't think so somehow .... we haven't had a Month this year with no news let's see ?

Also added this to site today

https://affyxell-com.translate.goog/bbs/?so_table=news&mode=VIEW&num=26&category&findType&findWord&sort1&sort2&page=1&PHPSESSID=1b4a4bd7f3328da8e465b2a847d9a4a4&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp&_x_tr_sch=http

Was 6 now 10 investors

https://affyxell-com.translate.goog/media/partner.php?PHPSESSID=1b4a4bd7f3328da8e465b2a847d9a4a4&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp&_x_tr_sch=http